Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 10/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SCN4A | P35499 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2263869 | 0.75 | KDM4E (0.32) | P2RX4LMNATSHRMAPK1SCN4A | |
| SCHEMBL3541130 | 0.75 | LMNA (0.34) | P2RX4LMNATSHRMAPK1SCN4A | |
| SCHEMBL31006068 | 0.75 | KDM4E (0.32) | P2RX4LMNATSHRMAPK1SCN4A | |
| SCHEMBL5792018 | 0.75 | LMNA (0.32) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL28222693 | 0.73 | LMNA (0.39) | P2RX4LMNATSHRMAPK1SCN4A | |
| SCHEMBL7029078 | 0.73 | P2RX4 (0.40) | P2RX4LMNATSHRMAPK1SCN4A | |
| SCHEMBL30081007 | 0.73 | P2RX4 (0.40) | P2RX4LMNATSHRMAPK1SCN4A | |
| SCHEMBL28784154 | 0.72 | P2RX4 (0.53) | P2RX4LMNATSHRMAPK1SCN4A | |
| SCHEMBL30843927 | 0.72 | SIGMAR1 (0.36) | P2RX4LMNA | |
| SCHEMBL28234956 | 0.72 | P2RX4 (0.34) | P2RX4P2RX1P2RX3P2RX7MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030004157-A1 | Use of NK-1 receptor antagonists against benign prostatic hyperplasia | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-02 | — | — | US | disclosed |
| US-5384405-A | Zinc reduction of nitrobenzoate to hydroxylamine then reduction with isothiocyanate | OLIN CORPORATION (US) | 1995-01-24 | — | — | US | disclosed |
| EP-0606304-A4 | N-HYDROXYQUINAZOLINONE AND 2-N-HYDROXYTHIOUREA BENZOATE COMPOUNDS AS BIOCIDES. | OLIN CORP (US) | 1994-11-09 | — | — | EP | disclosed |
| EP-0606304-A1 | N-HYDROXYQUINAZOLINONE AND 2-N-HYDROXYTHIOUREA BENZOATE COMPOUNDS AS BIOCIDES | OLIN CORPORATION (US) | 1994-07-20 | — | — | EP | disclosed |
| US-5298249-A | Uv stable fungicides | OLIN CORPORATION (US) | 1994-03-29 | — | — | US | disclosed |
| WO-1993006830-A1 | N-HYDROXYQUINAZOLINONE AND 2-N-HYDROXYTHIOUREA BENZOATE COMPOUNDS AS BIOCIDES | OLIN CORPORATION (US) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004157-A1 | Use of NK-1 receptor antagonists against benign prostatic hyperplasia | KLK3, TACR1, TACR2 | P2RX4 129/4885LMNA 3289/4885TSHR 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.